BeyondSpring(BYSI) - 2025 Q1 - Quarterly Results

Financial Performance - BeyondSpring reported a net loss from continuing operations of $2,584,000 for Q1 2025, a 24% increase compared to a net loss of $2,080,000 in Q1 2024[5] - The company reported a comprehensive income attributable to BeyondSpring Inc. of $4,380,000 for Q1 2025, compared to a comprehensive loss of $2,970,000 in Q1 2024[13] - The company reported a basic and diluted earnings per share of $0.11 for Q1 2025, compared to a loss of $0.08 in Q1 2024[13] Expenses - Research and development expenses increased by 21% to $874,000 in Q1 2025 from $721,000 in Q1 2024[5] - General and administrative expenses rose by 30% to $1,736,000 in Q1 2025 compared to $1,334,000 in Q1 2024[5] Assets and Cash Position - Cash and cash equivalents increased to $6,527,000 as of March 31, 2025, from $2,922,000 as of December 31, 2024[11] - Total current assets rose to $31,526,000 as of March 31, 2025, compared to $28,577,000 as of December 31, 2024[11] Product Development - Plinabulin has been administered to over 700 patients, showing a favorable safety profile and potential efficacy in cancer patients who have progressed on PD-1/L1 inhibitors[2] - The RBM39 molecular-glue degrader achieved complete tumor regression in Ewing sarcoma models and is on track for an IND submission in mid-2025[2] Discontinued Operations - The company currently owns approximately 40% of the outstanding equity interest in SEED, which is now classified as discontinued operations[4]